AbbVie Collaborates With Iambic On AI-Powered Discovery And Development Of Small Molecule Therapies

AbbVie announced a multi-year collaboration with clinical-stage life sciences technology company Iambic to accelerate discovery and development of small-molecule therapies in immunology. The partnership targets first-in-class and best-in-class candidates, providing a positive signal for AbbVie's early-stage pipeline, though no financial terms or development milestones were disclosed.